# Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

> **NCT04211545** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Rabeprazole
- **DRUG:** CC-92480

## Key facts

- **NCT ID:** NCT04211545
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-21
- **Primary completion:** 2019-12-26
- **Final completion:** 2019-12-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211545, "Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04211545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*